Edwards Lifesciences Corp (NYSE:EW) Position Lowered by Moreno Evelyn V

Moreno Evelyn V decreased its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 55.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,250 shares of the medical research company’s stock after selling 4,000 shares during the period. Moreno Evelyn V’s holdings in Edwards Lifesciences were worth $600,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Mercer Global Advisors Inc. ADV acquired a new stake in Edwards Lifesciences during the first quarter worth about $843,000. Wendell David Associates Inc. raised its position in shares of Edwards Lifesciences by 1.7% in the second quarter. Wendell David Associates Inc. now owns 12,100 shares of the medical research company’s stock valued at $2,235,000 after purchasing an additional 207 shares during the period. Wetherby Asset Management Inc. raised its position in shares of Edwards Lifesciences by 11.5% in the first quarter. Wetherby Asset Management Inc. now owns 3,273 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 337 shares during the period. Cambridge Investment Research Advisors Inc. raised its position in shares of Edwards Lifesciences by 7.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,553 shares of the medical research company’s stock valued at $3,741,000 after purchasing an additional 1,403 shares during the period. Finally, Ballentine Partners LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at about $243,000. 82.43% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Catherine M. Szyman sold 1,152 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $191.70, for a total transaction of $220,838.40. Following the completion of the transaction, the vice president now owns 19,162 shares of the company’s stock, valued at $3,673,355.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 1,474 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $184.55, for a total value of $272,026.70. Following the transaction, the vice president now directly owns 20,250 shares of the company’s stock, valued at approximately $3,737,137.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 142,948 shares of company stock worth $27,936,332. Company insiders own 1.63% of the company’s stock.

Edwards Lifesciences stock traded up $2.73 during trading hours on Thursday, reaching $216.24. 29,039 shares of the stock were exchanged, compared to its average volume of 1,186,828. The company has a market cap of $44.90 billion, a P/E ratio of 45.93, a P/E/G ratio of 2.72 and a beta of 0.87. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38. Edwards Lifesciences Corp has a twelve month low of $134.53 and a twelve month high of $219.71. The stock has a 50 day moving average price of $200.64.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the company posted $1.24 earnings per share. The business’s revenue for the quarter was up 15.2% on a year-over-year basis. On average, sell-side analysts predict that Edwards Lifesciences Corp will post 5.34 earnings per share for the current year.

Several brokerages have recently weighed in on EW. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 price objective on the stock in a research report on Thursday, July 25th. BTIG Research reaffirmed a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, July 25th. Wells Fargo & Co raised their price target on shares of Edwards Lifesciences from $207.00 to $220.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. BMO Capital Markets raised their price target on shares of Edwards Lifesciences from $204.00 to $224.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Deutsche Bank raised their price target on shares of Edwards Lifesciences from $164.00 to $184.00 and gave the stock a “hold” rating in a research report on Wednesday, April 24th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $204.74.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: The Structure of a Futures Contract

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.